Rongchang Bioc-Met Targets ADC for the first time in China to be approved clinically

On November 18, CDE's official website showed that Rongchang Bio's new class 1 drug, RC108 for injection, was approved clinically for c-Met-positive advanced malignant solid tumors.
RC108 is an ADC that targets c-Met, according to the Insight database.
c-MET is a subject tyrosine kinase that, by binding to its ligation hepatocellular growth factor (HGF), activates a number of different cell signaling paths, including cell signaling pathlines related to proliferation, movement, migration, and invasion, associated with poor prognosis of many types of solid tumors.
Insight data show that most of the c-MET targeted drugs currently under study in China are small molecule drugs, and only 4 antibody drugs are currently in clinical stage, namely, Xi'an Jansen's EGFR/c-Met dual anti-Amivantamab, AbbVie's ADC drug ABBV-399, Hengrui's ADC drug injection with SHR-A1403, and Upper Coast's EGFR/c-Met dual anti-EMB-01 injection.
's single anti-HLX55 has also been approved clinically, and has not yet been queried for start-up clinical.
from: Insight Database () In the c-Met small molecule targeting drug, there are currently 4 c-Met-related targeted drugs approved worldwide: Cabozantinib of Exelixis, Crizotinib of Pfizer, and Tepotinib of Merck Chipotinib and Novarma's Capmatinib, where carbotinib and clotinib are multi-target tyrosinease inhibitors, Tepotinib and Capmatinib are highly selective c-Met inhibitors approved in Japan and the United States in the first half of this year, respectively.
from: Insight Database ()